Core Insights - The Oncology Institute of Hope and Innovation (TOI) has launched a Lung Cancer Center of Excellence in Fort Lauderdale, Florida, aimed at providing advanced cancer care [1][2] - The center will be led by Dr. Edgardo S. Santos Castillero, a prominent thoracic oncologist known for his research and patient care [1][3] - TOI's mission is to enhance access to high-quality cancer care while reducing financial burdens for patients and payors [4] Company Overview - TOI was founded in 2007 and specializes in value-based cancer care, serving approximately 1.9 million patients [4] - The organization operates over 100 clinics and affiliate locations across five states, employing more than 180 clinicians [4] - TOI focuses on delivering evidence-based cancer treatments, including clinical trials and transfusions, in community settings [4] Treatment Approach - The Lung Cancer Center of Excellence aims to provide patients with access to advanced treatments and clinical trials in a compassionate environment [2][3] - The center emphasizes a whole-patient approach, integrating advanced diagnostics and innovative therapies [3] - TOI's vision includes redefining lung cancer care by combining advanced therapies with personalized treatment [4]

Core Insights - The Oncology Institute, Inc. (TOI) reported a strong financial performance for Q2 2025, achieving over 20% year-over-year revenue growth, primarily driven by a 40% increase in pharmacy business and the addition of over 50,000 new capitated lives [2][4][5] - The company is expanding its partnership with a major health plan in Florida, which is expected to double the number of lives covered under this payor [2][5] - TOI reaffirms its full-year 2025 revenue guidance of $460 to $480 million and anticipates achieving Adjusted EBITDA positivity by the end of 2025 [4][6] Financial Highlights - Consolidated revenue for Q2 2025 was $119.8 million, a 21.5% increase from $98.6 million in Q2 2024 [5][24] - Gross profit for the same period was $17.5 million, reflecting a 34.4% increase [5][24] - The net loss for Q2 2025 was $17.0 million, compared to a net loss of $15.5 million in Q2 2024 [5][24] - Adjusted EBITDA improved to $(4.1) million from $(8.7) million year-over-year [5][24] Operational Developments - The company expanded its fully delegated capitated partnership with Elevance into two new counties in Central Florida, which is expected to significantly increase the number of lives under its management [5][6] - TOI welcomed new executives, including Dr. Jeff Langsam as Chief Clinical Officer and Kristin England as Chief Administrative Officer, to enhance its operational capabilities [5][6] Key Metrics - The number of clinics remained stable at 80, while the number of markets increased to 20 from 14 year-over-year [21] - Lives under value-based contracts were approximately 1.9 million, consistent with the previous year [22] Cash Position - As of June 30, 2025, TOI had cash and cash equivalents of $30.3 million, down from $49.7 million at the end of 2024 [23][25] - The company reported a net cash outflow from operating activities of $15.2 million for the first half of 2025, a significant improvement from $31.5 million in the same period of 2024 [25][26]